Bextra and Vioxx Withdrawal Spawn Advertising Pause from Bristol Myers
Pharmaceutical giant Bristol Myers Squibb has announced that they will suspend direct-to-consumer advertising for their prescription drug products for a year. This comes in the wake of the well-publicized withdrawals of Merck's Vioxx and Pfizer's Bextra, two non-steroidal anti-inflammatory drugs (NSAIDs) that were voluntarily withdrawn from the market recently. Studies showed that they increase the likelihood of strokes and heart attacks among patients that take them for prolonged periods of time. This represents an unusual move for a pharmaceutical company, as they tend to spend a large portion of their annual advertising budget on direct-to-consumer advertising.
It is possible that Bristol Myers recognizes that consumers are becoming concerned about new drugs being approved by the FDA and advertised heavily, only to find out later that the drugs have previously unknown and possibly dangerous side effects. Consumers have learned that advertising a drug as "new and improved" doesn't necessarily mean that it is new, or improved, or even safe. In short, customers are suspicious of pharmaceutical advertising, and the drug companies are to be commended for taking notice of that fact.
Since 1997, drug companies have been allowed by U.S. law to advertise directly to consumers. This has led to an astonishing number of ads on television and radio, as consumers see ads showing one happy person after another. The ads suggest that the happiness shown is a result of the use of the product, and a voiceover quickly mumbles through the known, and sometimes lengthy, list of side effects. Patients are encouraged to speak with their doctor, and they have been doing so in record numbers. The problem, as Bristol Myers know realizes, is that consumers are well aware that the withdrawn Bextra and Vioxx were advertised as being safe. This has naturally led to a general suspicion of all advertised drugs, and Bristol Myers correctly sees that they could be the victims of a drug-company backlash, even if they didn't manufacture any of the withdrawn products.
This will probably save Bristol Myers a lot of money in the short term, as their advertising would have largely gone to waste. The Food and Drug Administration is taking steps to make sure that the drugs that reach the U.S. market are safe, and in time, the public will again become more trusting of pharmaceutical advertising. In the meantime, TV viewers will be spared from having to watch the sometimes-cryptic drug ads, which often prompt questions of "What does this drug do?"
©Copyright 2005 by Retro Marketing.
Charles Essmeier is the owner of Retro Marketing, a firm devoted to informational Websites, including Bextra-Info.net, a site devoted to the withdrawn drug Bextra and StructuredSettlementHelp.com, a site devoted to structured settlements.
Latest News
BioImagene CEO, Dr. Ajit Singh, Speaks On Enabling Personalized ... MarketWatch - Digital pathology, a key enabler for personalized medicine, will aid clinicians in managing and interpreting data from a whole new set of diagnostic tests ... Aperio Introduces SecondSlide(TM) Digital Slide Sharing Network |
 Boston Globe | Medicine for the Job Market New York Times, United States - By JONATHAN GRUBER A CENTRAL feature of Barack Obama’s presidential campaign was an aggressive plan to expand health insurance coverage by subsidizing ... New Report Shows Slower Premium Growth, But Increasing Pressure to ... Health Corps Research database from the US Library of Medicine |
 Current World News | American College of Surgeons Comments on Institute of Medicine ... MarketWatch - CHICAGO, Dec 03, 2008 /PRNewswire-USNewswire via COMTEX/ -- The American College of Surgeons (ACS) today recognized the Institute of Medicine (IOM) for its ... BMC Internal Medicine Residency Program Achieves National ... Report urges more sleep for medical residents Medical Residents Must Sleep After 16 Hours, Experts Urge |
Research and Markets: 2008 Integrative Medicine and Dietary ... MarketWatch - In this 32-page issue, we offer a breakdown of 2007 US Complementary and Alternative Medicine sales data and provides a detailed analysis of new integrative ... |
 Afrik.com | 34 Nigerian Children Dead From Tainted Medicine Voice of America - By VOA News Nigerian health officials say they are flying in doses of an antidote for a poisoned teething medicine that has now killed 34 infants. ... 'Toxic' syrup kills Nigerian babies Teething mixture kills more Nigerian babies Nigeria infant drug toll hits 34, antidote flown in |
Research database from the US Library of Medicine The Plain Dealer - cleveland.com, OH - Search PubMed, Clinicaltrials.gov, the CDC and a dozen other medical sites - all at once. AP MEDICAL VIDEO by Michael O'Malley and Joan Mazzolini/Plain ... |
A New Index of Preventive Medicine Companies Motley Fool - The accompanying table [click to enlarge] presents statistics and the top 15 rated companies in the ETF Innovators [ETFI] Preventive Medicine Index. ... |
American Academy of Dermatology Issues Position Statement on Vitamin D MarketWatch - The currently recommended adequate intake levels established by the Institute of Medicine may be revised upward due to evolving research on the increasing ... |
NIGERIA: Jos displaced grapple with food, water, medicine shortages IRINnews.org, NY - JOS, 4 December 2008 (IRIN) - Water, medicine and food supplies are running low for an estimated 10000 people displaced by violence in Jos, northern Nigeria ... |
 Canada.com | "Rogue" stem cell clinics exploit hope: report Reuters - "The direct-to-consumer portrayal of stem cell medicine is optimistic and unsupported by published evidence," Timothy Caulfield of the University of Alberta ... Scientists warn of “rogue” online stem cell clinics Internet stem-cell clinics 'exploiting' MS and Parkinson's patients The International Society for Stem Cell Research Releases New ... |
Resources
-
Sorry Currently Unavailable